Literature DB >> 27770068

Death with dignity in Washington patients with amyotrophic lateral sclerosis.

Leo H Wang1, Michael A Elliott2, Lily Jung Henson2, Elba Gerena-Maldonado2, Susan Strom2, Sharon Downing2, Jennifer Vetrovs2, Paige Kayihan2, Piper Paul2, Kate Kennedy2, Joshua O Benditt2, Michael D Weiss2.   

Abstract

OBJECTIVES: To describe the amyotrophic lateral sclerosis (ALS) patients who sought medication under the Washington State Death with Dignity (DWD) Act since its inception in 2009.
METHODS: Chart review at 3 tertiary medical centers in the Seattle/Puget Sound region and comparison to publicly available data of ALS and all-cause DWD cohorts from Washington and Oregon.
RESULTS: In Washington State, 39 patients with ALS requested DWD from the University of Washington, Virginia Mason, and Swedish Medical Centers beginning in 2009. The median age at death was 65 years (range 46-86). Seventy-seven percent of the patients used the prescriptions. All of the patients who used the medications passed away without complications. The major reasons for patients to request DWD as reported by participating physicians were loss of autonomy and dignity and decrease in enjoyable activities. Inadequate pain control, financial cost, and loss of bodily control were less commonly indicated. These findings were similar to those of the 92 patients who sought DWD in Oregon. In Washington and Oregon, the percentage of patients with ALS seeking DWD is higher compared to the cancer DWD cohort. Furthermore, compared to the all-cause DWD cohort, patients with ALS are more likely to be non-Hispanic white, married, educated, enrolled in hospice, and to have died at home.
CONCLUSIONS: Although a small number, ALS represents the disease with the highest proportion of patients seeking to participate in DWD. Patients with ALS who choose DWD are well-educated and have access to palliative or life-prolonging care. The use of the medications appears to be able to achieve the patients' goals without complications.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 27770068      PMCID: PMC5109936          DOI: 10.1212/WNL.0000000000003335

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington.

Authors:  Linda Ganzini; Maria J Silveira; Wendy S Johnston
Journal:  J Pain Symptom Manage       Date:  2002-09       Impact factor: 3.612

3.  Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration.

Authors:  Anne M Lipton; Charles L White; Eileen H Bigio
Journal:  Acta Neuropathol       Date:  2004-09-04       Impact factor: 17.088

4.  The 10-year experience of Oregon's Death with Dignity Act: 1998-2007.

Authors:  Katrina Hedberg; David Hopkins; Richard Leman; Melvin Kohn
Journal:  J Clin Ethics       Date:  2009

5.  Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study.

Authors:  Maud Maessen; Jan H Veldink; Bregje D Onwuteaka-Philipsen; Henk T Hendricks; Helenius J Schelhaas; Hepke F Grupstra; Gerrit van der Wal; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

6.  Are amyotrophic lateral sclerosis patients cognitively normal?

Authors:  C Lomen-Hoerth; J Murphy; S Langmore; J H Kramer; R K Olney; B Miller
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

7.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

8.  Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands.

Authors:  Jan H Veldink; John H J Wokke; Gerrit van der Wal; J M B Vianney de Jong; Leonard H van den Berg
Journal:  N Engl J Med       Date:  2002-05-23       Impact factor: 91.245

9.  Trends and determinants of end-of-life practices in ALS in the Netherlands.

Authors:  M Maessen; Jan H Veldink; B D Onwuteaka-Philipsen; J M de Vries; J H J Wokke; G van der Wal; L H van den Berg
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

10.  Implementing a Death with Dignity program at a comprehensive cancer center.

Authors:  Elizabeth Trice Loggers; Helene Starks; Moreen Shannon-Dudley; Anthony L Back; Frederick R Appelbaum; F Marc Stewart
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

View more
  4 in total

1.  Access to Aid-in-Dying in the United States: Shifting the Debate From Rights to Justice.

Authors:  Mara Buchbinder
Journal:  Am J Public Health       Date:  2018-04-19       Impact factor: 9.308

2.  Health Care Providers' Experiences with Implementing Medical Aid-in-Dying in Vermont: a Qualitative Study.

Authors:  Mara Buchbinder; Elizabeth R Brassfield; Manisha Mishra
Journal:  J Gen Intern Med       Date:  2019-01-25       Impact factor: 5.128

Review 3.  Talking about the end of life: communication patterns in amyotrophic lateral sclerosis - a scoping review.

Authors:  Anke Erdmann; Celia Spoden; Irene Hirschberg; Gerald Neitzke
Journal:  Palliat Care Soc Pract       Date:  2022-03-15

4.  Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study.

Authors:  Remko M van Eenennaam; Loulou S Koppenol; Willeke J Kruithof; Esther T Kruitwagen-van Reenen; Sotice Pieters; Michael A van Es; Leonard H van den Berg; Johanna M A Visser-Meily; Anita Beelen
Journal:  Brain Sci       Date:  2021-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.